Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
Oxaliplatin and 5-fluorouracil have a significant activity in locally advanced oesophageal squamous cell cancer (OSCC). However, their optimal dosage and efficacy when combined with concurrent radiotherapy as neoadjuvant treatment are unknown. This non-randomised, phase I/II study aimed to define the maximum tolerated dose (MTD) and assessed the histopathological tumour response rate to neoadjuvant oxaliplatin in weekly escalating doses (40, 45, 50 mg m(-2)) and continuous infusional 5-fluorouracil (CI-5FU; 225 mg m(-2)) plus concurrent radiotherapy. Patients had resectable OSCC. Resection was scheduled for 4-6 weeks after chemoradiotherapy. During phase I (dose escalation; n=19), weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) was established as the MTD and was the recommended dosage for phase II. Oesophageal mucositis was the dose-limiting toxicity at higher doses. During phase II, histopathological responses (<10% residual tumour cells within the specimen) were observed in 10 of 16 patients (63%; 95% confidence interval: 39-82%). Overall, 16 of the 25 patients (64%) who underwent resection had a histopathological response; tumour-free resection (R0) was achieved in 80%. Neoadjuvant weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) with concurrent radiotherapy provides promising histological response rates and R0 resection rates in locally advanced OSCC.
Lorenzen
S
S
Third Department of Internal Medicine (Haematology/Medical Oncology), Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Brücher
B
B
Zimmermann
F
F
Geinitz
H
H
Riera
J
J
Schuster
T
T
Roethling
N
N
Höfler
H
H
Ott
K
K
Peschel
C
C
Siewert
J R
JR
Molls
M
M
Lordick
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil
Ann Surg. 2005 May;241(5):810-7; discussion 817-20
15849517
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1092-8
11958906
J Clin Oncol. 2007 Aug 20;25(24):3719-25
17704421
Cancer. 2001 Jul 15;92(2):279-86
11466680
Br J Cancer. 2005 Jul 25;93(2):190-4
16012522
Control Clin Trials. 1996 Aug;17(4):343-6
8889347
Langenbecks Arch Chir. 1988;373(6):367-76
3210852
Ann Oncol. 2005 Dec;16(12):1898-905
16219623
Ann Surg. 2002 Sep;236(3):376-84; discussion 384-5
12192324
J Clin Oncol. 2000 Feb;18(4):868-76
10673530
Ann Oncol. 2005 Jul;16(7):1140-6
15894548
Br J Surg. 1998 Jun;85(6):840-4
9667720
J Clin Oncol. 1996 Jan;14(1):156-63
8558191
Lancet Oncol. 2007 Mar;8(3):226-34
17329193
J Chronic Dis. 1961 Apr;13:346-53
13704181
N Engl J Med. 1997 Jul 17;337(3):161-7
9219702
N Engl J Med. 1992 Jun 11;326(24):1593-8
1584260
Cancer. 2003 Oct 1;98(7):1521-30
14508841
J Clin Oncol. 2007 Sep 20;25(27):4217-23
17548840
J Clin Oncol. 2007 Apr 1;25(10):1160-8
17401004
Ann Surg Oncol. 2008 Jan;15(1):88-95
17896144
J Clin Oncol. 1996 Mar;14(3):829-37
8622031
Ann Thorac Surg. 2003 Jun;75(6):1720-6
12822606
J Clin Oncol. 2007 Jan 1;25(1):110-7
17194912
Clin Colorectal Cancer. 2002 May;2(1):24-30
12453333
Cancer J. 2003 Jul-Aug;9(4):251-60
12967135
Cancer. 2006 May 15;106(10):2119-27
16607651
N Engl J Med. 1996 Aug 15;335(7):462-7
8672151
J Clin Oncol. 2005 Apr 1;23(10):2310-7
15800321
Cancer. 2001 Apr 15;91(8):1574-8
11301408
J Clin Oncol. 1997 Jan;15(1):277-84
8996153
J Clin Oncol. 2008 Mar 1;26(7):1086-92
18309943
Oncology. 2003;64(3):280-7
12697970
J Clin Oncol. 2002 Jun 15;20(12):2844-50
12065561